BioPharmSignal logoBioPharmSignal

Biotech News

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Tango Therapeutics (TNGX)Tango TherapeuticsCompany update

- Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed

Related news

TNGXTango Therapeutics2026-06-08 10:59 EST

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

TNGXTango Therapeutics2026-08-11 11:00 EST

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

KYMRKymera2026-06-08 20:01 EST

Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

GSKGSK plc2026-07-28 12:00 EST

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

MMSIMerit Medical2026-08-19 20:05 EST

Merit Medical Announces Global Operations Leadership Transition

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

ERASErasca2026-08-10 12:00 EST

Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

View all latest news

Tango Therapeutics

Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen...

Recent company news

TNGXTango Therapeutics2026-08-11 11:00 EST

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

TNGXTango Therapeutics2026-08-06 22:24 EST

Tango Therapeutics Announces Executive Chair Transition

TNGXTango Therapeutics2026-06-22 20:05 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

TNGXTango Therapeutics2026-06-10 02:50 EST

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

TNGXTango Therapeutics2026-06-08 20:01 EST

Tango Therapeutics Announces Proposed $500 Million Public Offering

Stock data

Close
23.88 USD
Market cap
3.11B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States